Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: A positron emission tomography study with [11C]McN 5652

Justine M. Kent, Jeremy D. Coplan, Ilise Lombardo, Dah Ren Hwang, Yiyun Huang, Osama Mawlawi, Ronald L. Van Heertum, Mark Slifstein, Anissa Abi-Dargham, Jack M. Gorman, Marc Laruelle

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Rationale: Although selective serotonin reuptake inhibitors (SSRIs) are widely used in the treatment of anxiety and depressive disorders, the occupancy of the serotonin reuptake transporter (SERT) achieved in humans at typical clinical doses by these agents remains poorly characterized. Objective: The purpose of this study was to determine the occupancy of the SERT achieved in vivo by the SSRI paroxetine in social phobia patients at typical antianxiety doses. Methods: Measures of SERT availability were obtained with positron emission tomography and the SERT radiotracer [11C](+)-McN 5652 in five patients with social phobia before and during treatment with paroxetine at usual therapeutic doses (20-40 mg per day). Results: Occupancy of the SERT by paroxetine was high in all subjects and in all regions measured after 3-6 months of continuous treatment. Conclusions: The results of this study in an anxiety disorder sample are consistent with previously reported results in a depressed sample and suggest that paroxetine at therapeutic doses achieves very high occupancy levels of the SERT.

Original languageEnglish (US)
Pages (from-to)341-348
Number of pages8
JournalPsychopharmacology
Volume164
Issue number4
DOIs
StatePublished - Dec 19 2002

Fingerprint

Paroxetine
Serotonin Plasma Membrane Transport Proteins
Positron-Emission Tomography
Brain
Serotonin Uptake Inhibitors
Anxiety Disorders
Therapeutics
Depressive Disorder
Social Phobia
McN 5652

Keywords

  • Occupancy
  • Paroxetine
  • Pharmacology
  • Selective serotonin reuptake inhibitors
  • Serotonin reuptake transporter
  • Social phobia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia : A positron emission tomography study with [11C]McN 5652. / Kent, Justine M.; Coplan, Jeremy D.; Lombardo, Ilise; Hwang, Dah Ren; Huang, Yiyun; Mawlawi, Osama; Van Heertum, Ronald L.; Slifstein, Mark; Abi-Dargham, Anissa; Gorman, Jack M.; Laruelle, Marc.

In: Psychopharmacology, Vol. 164, No. 4, 19.12.2002, p. 341-348.

Research output: Contribution to journalArticle

Kent, JM, Coplan, JD, Lombardo, I, Hwang, DR, Huang, Y, Mawlawi, O, Van Heertum, RL, Slifstein, M, Abi-Dargham, A, Gorman, JM & Laruelle, M 2002, 'Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: A positron emission tomography study with [11C]McN 5652', Psychopharmacology, vol. 164, no. 4, pp. 341-348. https://doi.org/10.1007/s00213-002-1218-8
Kent, Justine M. ; Coplan, Jeremy D. ; Lombardo, Ilise ; Hwang, Dah Ren ; Huang, Yiyun ; Mawlawi, Osama ; Van Heertum, Ronald L. ; Slifstein, Mark ; Abi-Dargham, Anissa ; Gorman, Jack M. ; Laruelle, Marc. / Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia : A positron emission tomography study with [11C]McN 5652. In: Psychopharmacology. 2002 ; Vol. 164, No. 4. pp. 341-348.
@article{2d3f6ce7a7b74fcab421347a1422206e,
title = "Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: A positron emission tomography study with [11C]McN 5652",
abstract = "Rationale: Although selective serotonin reuptake inhibitors (SSRIs) are widely used in the treatment of anxiety and depressive disorders, the occupancy of the serotonin reuptake transporter (SERT) achieved in humans at typical clinical doses by these agents remains poorly characterized. Objective: The purpose of this study was to determine the occupancy of the SERT achieved in vivo by the SSRI paroxetine in social phobia patients at typical antianxiety doses. Methods: Measures of SERT availability were obtained with positron emission tomography and the SERT radiotracer [11C](+)-McN 5652 in five patients with social phobia before and during treatment with paroxetine at usual therapeutic doses (20-40 mg per day). Results: Occupancy of the SERT by paroxetine was high in all subjects and in all regions measured after 3-6 months of continuous treatment. Conclusions: The results of this study in an anxiety disorder sample are consistent with previously reported results in a depressed sample and suggest that paroxetine at therapeutic doses achieves very high occupancy levels of the SERT.",
keywords = "Occupancy, Paroxetine, Pharmacology, Selective serotonin reuptake inhibitors, Serotonin reuptake transporter, Social phobia",
author = "Kent, {Justine M.} and Coplan, {Jeremy D.} and Ilise Lombardo and Hwang, {Dah Ren} and Yiyun Huang and Osama Mawlawi and {Van Heertum}, {Ronald L.} and Mark Slifstein and Anissa Abi-Dargham and Gorman, {Jack M.} and Marc Laruelle",
year = "2002",
month = "12",
day = "19",
doi = "10.1007/s00213-002-1218-8",
language = "English (US)",
volume = "164",
pages = "341--348",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia

T2 - A positron emission tomography study with [11C]McN 5652

AU - Kent, Justine M.

AU - Coplan, Jeremy D.

AU - Lombardo, Ilise

AU - Hwang, Dah Ren

AU - Huang, Yiyun

AU - Mawlawi, Osama

AU - Van Heertum, Ronald L.

AU - Slifstein, Mark

AU - Abi-Dargham, Anissa

AU - Gorman, Jack M.

AU - Laruelle, Marc

PY - 2002/12/19

Y1 - 2002/12/19

N2 - Rationale: Although selective serotonin reuptake inhibitors (SSRIs) are widely used in the treatment of anxiety and depressive disorders, the occupancy of the serotonin reuptake transporter (SERT) achieved in humans at typical clinical doses by these agents remains poorly characterized. Objective: The purpose of this study was to determine the occupancy of the SERT achieved in vivo by the SSRI paroxetine in social phobia patients at typical antianxiety doses. Methods: Measures of SERT availability were obtained with positron emission tomography and the SERT radiotracer [11C](+)-McN 5652 in five patients with social phobia before and during treatment with paroxetine at usual therapeutic doses (20-40 mg per day). Results: Occupancy of the SERT by paroxetine was high in all subjects and in all regions measured after 3-6 months of continuous treatment. Conclusions: The results of this study in an anxiety disorder sample are consistent with previously reported results in a depressed sample and suggest that paroxetine at therapeutic doses achieves very high occupancy levels of the SERT.

AB - Rationale: Although selective serotonin reuptake inhibitors (SSRIs) are widely used in the treatment of anxiety and depressive disorders, the occupancy of the serotonin reuptake transporter (SERT) achieved in humans at typical clinical doses by these agents remains poorly characterized. Objective: The purpose of this study was to determine the occupancy of the SERT achieved in vivo by the SSRI paroxetine in social phobia patients at typical antianxiety doses. Methods: Measures of SERT availability were obtained with positron emission tomography and the SERT radiotracer [11C](+)-McN 5652 in five patients with social phobia before and during treatment with paroxetine at usual therapeutic doses (20-40 mg per day). Results: Occupancy of the SERT by paroxetine was high in all subjects and in all regions measured after 3-6 months of continuous treatment. Conclusions: The results of this study in an anxiety disorder sample are consistent with previously reported results in a depressed sample and suggest that paroxetine at therapeutic doses achieves very high occupancy levels of the SERT.

KW - Occupancy

KW - Paroxetine

KW - Pharmacology

KW - Selective serotonin reuptake inhibitors

KW - Serotonin reuptake transporter

KW - Social phobia

UR - http://www.scopus.com/inward/record.url?scp=0036451764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036451764&partnerID=8YFLogxK

U2 - 10.1007/s00213-002-1218-8

DO - 10.1007/s00213-002-1218-8

M3 - Article

C2 - 12457263

AN - SCOPUS:0036451764

VL - 164

SP - 341

EP - 348

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 4

ER -